DMXE
DMXE is a designer dissociative of the arylcyclohexylamine class, structurally related to methoxetamine (MXE) in which the 3-methoxy group is replaced by a methyl substituent. It emerged on the recreational drug market around October 20201 and was first formally identified by a forensic laboratory in Denmark in February 2021.2 As a relatively novel research chemical, limited data exists regarding its safety profile, pharmacology, and long-term health effects.
Contents
Dosage & Duration
Dosage
Duration
Subjective Effects
DMXE is an arylcyclohexylamine designer drug reported to produce dissociative effects. The available material does not describe the character, intensity curve, or duration of the subjective experience in further detail.
Cognitive
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
DMXE (deoxymethoxetamine) is an arylcyclohexylamine and a structural analogue of methoxetamine in which the 3-methoxy group is replaced by a methyl group.3 Its detailed receptor-level pharmacology has not been characterized in the available literature.
Pharmacokinetics
Tolerance
Dissociatives, NMDA receptor antagonists
Harm Potential
History & Culture
DMXE emerged as a novel research chemical around October 2020, when it first appeared on online designer drug markets.1 The compound is structurally derived from methoxetamine (MXE), with the 3-methoxy substituent replaced by a methyl group—hence its alternative designation…
Legality
References
Source Pages
Citations
- (March 26, 2021). Alert from NDEWS Web Monitoring team: Increases in Reddit discussions of DMXE, October 2020–March 2021. National Drug Early Warning System (NDEWS). https://ndews.org/wordpress/files/2024/03/NDEWS-Weekly-Briefing-Issue-28.pdf12
- Skinnider MA, Wang F, Pasin D, Greiner R, Foster LJ, Dalsgaard PK, & Wishart DS. (2021). A deep generative model enables automated structure elucidation of novel psychoactive substances. Nature Machine Intelligence, 3, 973-984. https://doi.org/10.1038/s42256-021-00407-x1
- Irie T, Yanase Y, Demizu Y, Usami M, & Kikura-Hanajiri R. (2022). Derivatives of methoxetamine and major methoxetamine metabolites potently block NMDA receptors. 150(4), 233-243. https://doi.org/10.1016/j.jphs.2022.09.0031
- (2022). AddictedChem: A Data-Driven Integrated Platform for New Psychoactive Substance Identification. https://doi.org/10.3390/molecules271239311
- (October 28, 2025). Deoxymethoxetamine — NPS Discovery New Drug Monograph. Center for Forensic Science Research and Education (CFSRE). https://www.cfsre.org/nps-discovery/monographs/deoxymethoxetamine1
Further Reading
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the DMXE article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.